Crossmark

672 Phase I clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in patients with recurrent ovarian cancer (OVCA)

Crossref DOI link: https://doi.org/10.1136/jitc-2022-SITC2022.0672

Published Online: 2022-11-07

Published Print: 2022-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Wenham, Robert

Davila, Marco

Abate-Daga, Daniel

McGettigan, Melissa

Wang, Xuefeng

Boyle, Theresa

Garzone, Pamela

Kumar, Amit

Conejo-Garcia, Jose
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct05316129 at ClinicalTrials.gov

Documents that mention this clinical trial

TP014/#1586 Phase I clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer (OVCA)
https://doi.org/10.1136/ijgc-2024-igcs.616

672 Phase I clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in patients with recurrent ovarian cancer (OVCA)
https://doi.org/10.1136/jitc-2022-sitc2022.0672

Document is current

Any future updates will be listed below